Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|MAP2K1 Q56_V60del||ovarian serous carcinoma||predicted - sensitive||MEK inhibitor (Pan) MEK1 Inhibitor||Selumetinib||Case Reports/Case Series||Actionable||In a Phase II trial, Koselugo (selumetinib) treatment resulted in a complete response that lasted over 5 years with continuous treatment in a patient with serous ovarian cancer harboring MAP2K1 Q56_V60del (PMID: 26324360).||26324360|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|